Spexis Announces Changes to the Executive Committee
01 nov. 2023 02h20 HE
|
Spexis AG
Spexis Announces Changes to the Executive Committee
Spexis to host business update conference call on October 9, 2023
06 oct. 2023 01h30 HE
|
Spexis AG
Spexis to host business update conference call on October 9, 2023
Spexis provides business update and announces financial results for the first half of 2023
29 sept. 2023 01h30 HE
|
Spexis AG
Spexis provides business update and announces financial results for the first half of 2023
Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology
28 sept. 2023 01h30 HE
|
Spexis AG
Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology
Spexis announces USD $2.5 million capital commitment to support the upcoming Phase 3 ColiFin® studies
15 août 2023 01h15 HE
|
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR ALLSCHWIL, Switzerland, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle...
Spexis announces the publication of promising results for a novel class of macrocyclic, peptidomimetic antibiotics in Science Advances demonstrating potent in vitro and in vivo antimicrobial activity against MDR and XDR Enterobacteriaceae, including carbapenem-resistant and colistin-resistant strains
07 juin 2023 01h15 HE
|
Spexis AG
ALLSCHWIL, Switzerland, June 06, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced the publication of...
Spexis provides business update and announces financial results for the full year 2022
30 mai 2023 01h15 HE
|
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR USD 4.5 million capital commitment from SPRIM Global Investments to enable initiation of ColiFin® COPILOT study; first patient dosing expected in...
Spexis announces closing of capital commitment of USD 4.5 million from SPRIM Global Investments (SGI) to enable initiation of ColiFin® Phase 3 study
18 avr. 2023 02h23 HE
|
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR Funding to enable immediate initiation of the COPILOT study, the first of two Phase 3 ColiFin® studies; first-patient-in expected in June 2023Commitment...
Spexis reports solid safety and pharmacokinetics results from first-in-human study with inhaled murepavadin, a novel macrocycle compound
09 janv. 2023 01h20 HE
|
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR Inhaled murepavadin shown to be well tolerated at all dose levels Program derived from Spexis’ macrocycle platformData support moving forward...
Spexis provides business update
28 juil. 2022 01h20 HE
|
Spexis AG
Cash position to finance operations extended into January 2023Resources focused on advancing lead program, Phase 3 ColiFin®Assessment of balixafortide development options continues; balixafortide...